Adolfo A. Ferrando, MD, PhD

Academic Appointments

  • Professor of Pediatrics
  • Professor of Pathology and Cell Biology and of Systems Biology (in the Institute for Cancer Genetics)

Current Administrative Positions

  • Associate Director for Shared Resources, Herbert Irving Comprehensive Cancer Center
Adolfo A. Ferrando, MD, PhD

Email: af2196@cumc.columbia.edu

The research program in the Ferrando lab combines genomics, biochemical, genetic and experimental therapeutics approaches towards the identification of novel therapies for the treatment of high-risk leukemias and lymphomas. His laboratory has played major roles in the functional analysis of oncogenic NOTCH1 and the TLX1 and TLX3 oncogenes in the pathogenesis of T-ALL. In addition, he has identified and functionally characterized numerous genes somatically mutated in this disease including PTEN, WT1, PHF6, BCL11B, ETV6, EZH2 and NT5C2 as well as in peripheral T-cell lymphomas. Identifying and targeting major leukemia driver oncogenes by leveraging mouse models and forward genomics and deciphering the basic mechanisms underlying leukemic transformation and drug resistance are major areas of active research in the Ferrando lab.

Departments and Divisions

  • Department of Pediatrics
    Division of Pediatric Hematology, Oncology, and Stem Cell Transplantation
  • Department of Pathology & Cell Biology

Centers / Institutes / Programs

  • Herbert Irving Comprehensive Cancer Center

NIH Grants

  • ECOG-ACRIN INTEGRATED LEUKEMIA TRANSLATIONAL RESEARCH CENTER (Federal Gov)

    Mar 7 2019 - Feb 28 2025

    MOLECULAR PATHWAYS AND TARGETED THERAPIES IN HUMAN LEUKEMIA (Federal Gov)

    Sep 30 2017 - Aug 31 2024

    MASTER REGULATORS OF DRUG RESISTANCE IN RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA (Private)

    Jul 1 2019 - Jun 30 2023

    MOLECULAR CHARACTERIZATION AND TARGETING OF NT5C2 MUTATIONS IN ACUTE LYMPHOBLASTIC LEUKEMIA (Federal Gov)

    Aug 1 2017 - Jul 31 2022

    ROLE AND MECHANISMS OF ENHANCER DEREGULATION IN T-ALL (Private)

    Jul 1 2019 - Jun 30 2022

    THE ROLE OF A NOVEL FUSION ONCOGENE FYN-TRAF3IP2 IN PERIPHERAL T-CELL LYMPHOMA (Federal Gov)

    Feb 1 2018 - Jan 31 2022

    TARGETING METABOLIC VULNERABILITIES IN ETP-AL (Private)

    Jul 1 2017 - Jun 30 2021

    MOLECULAR MECHANISMS OF PHF6 MUTATIONS IN LEUKEMOGENESIS (Private)

    Jul 1 2019 - Jun 30 2021

    NEW THERAPIES IN RELAPSED ALL (Private)

    Oct 1 2017 - Sep 30 2020

    THE ROLE OF NOTCH1 CONTROLLED MICROPEPTIDES IN T-ALL (Private)

    Jul 1 2017 - Jun 30 2020

    PLATFORM DEVELOPMENT FOR TARGET IDENTIFICATION IN HIGH RISK PEDIATRIC LEUKEMIAS (Private)

    Apr 1 2019 - Mar 31 2020

    OVERCOMING CHEMOTHERAPY RESISTANCE IN CHILDHO (Private)

    Dec 31 2017 - Dec 31 2019

    MECHANISMS OF CHEMOTHERAPY RESISTANCE IN ACUTE LYMPHOBLASTIC LEUKEMIA (Private)

    Jan 1 2018 - Dec 31 2019

    TARGETING METABOLIC VULNERABILITIES IN ETP-AL (Private)

    Oct 1 2017 - Sep 30 2019

    MECHANISMS OF CHEMOTHERAPY RESISTANCE IN ACUTE LYMPHOBLASTIC LEUKEMIA (Private)

    Sep 1 2017 - Aug 31 2019

    CANCER CENTER SUPPORT GRANT (Federal Gov)

    Jul 1 2014 - Jun 30 2019

    CANCER CENTER SUPPORT GRANT (Federal Gov)

    Jul 1 2014 - Jun 30 2019

    CANCER CENTER SUPPORT GRANT (Federal Gov)

    Jul 1 2014 - Jun 30 2019

    DEVELOPMENT OF NT5C2 INHIBITORS FOR TREATMENT OF RELAPSED REFRACTORY ALL (Private)

    Jul 1 2017 - Jun 30 2019

    THE GENETICS AND MECHANISM OF CHEMOTHERAPY RESISTANCE IN ALL (Private)

    Jul 1 2018 - Jun 30 2019

    BRINGING ANTI-NOTCH1 THERAPIES TO THE CLINIC (Private)

    Oct 1 2017 - Sep 30 2018

    NEW METABOLIC TARGETS IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) (Private)

    Jul 1 2016 - Jun 30 2018

    THE GENETICS AND MECHANISM OF CHEMOTHERAPY RESISTANCE IN ALL (Private)

    Jul 1 2017 - Jun 30 2018

    THE ROLE OF VAV1 MUTATIONS IN PERIPHERAL T-CELL LYMPHOMAS (Private)

    Jul 1 2016 - Jun 30 2018

    THE ROLE OF NOTCH1 IN THE PATHOGENESIS OF CLL (Federal Gov)

    Apr 1 2013 - Mar 31 2018

    THE ROLE OF NOTCH1 IN THE PATHOGENESIS OF CLL (Federal Gov)

    Apr 1 2013 - Mar 31 2018

    THE ROLE OF NOTCH1 IN THE PATHOGENESIS OF CLL (Federal Gov)

    Apr 1 2013 - Mar 31 2018

    THE ROLE OF ETV6 IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA. (Federal Gov)

    Feb 1 2013 - Jan 31 2018

    THE ROLE OF ETV6 IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA. (Federal Gov)

    Feb 1 2013 - Jan 31 2018

    MECHANISMS OF CHEMOTHERAPY RESISTANCE IN ACUTE LYMPHOBLASTIC LEUKEMIA (Private)

    Jan 1 2016 - Dec 31 2017

    EMERGING TARGETS IN LYMPHOID MALIGNANCIES: PROJECT 4 - OVERCOMING GLUCOCORTICOID RESISTANCE IN ALL (Private)

    Oct 1 2012 - Sep 30 2017

    TARGETING CHEMOTHERAPY RESISTANCE IN T-ALL (Private)

    Oct 1 2014 - Sep 30 2017

    BRINGING ANTI-NOTCH1 THERAPIES TO THE CLINIC (Private)

    Oct 1 2014 - Sep 30 2017

    PRECISION-BASED THERAPY FOR CHILDHOOD LEUKEMIA (Private)

    Jul 1 2016 - Jun 30 2017

    FUNCTIONAL DISSECTION OF ONCOGENIC ENHANCERS (Federal Gov)

    Jul 1 2015 - Jun 30 2017

    FUNCTIONAL DISSECTION OF ONCOGENIC ENHANCERS IN T-ALL (Private)

    Jul 1 2015 - Jun 30 2017

    NEW METABOLIC TARGETS IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) (Private)

    Jul 1 2016 - Jun 30 2017

    FUNCTIONAL DISSECTION OF ONCOGENIC ENHANCERS (Federal Gov)

    Jul 1 2015 - Jun 30 2017

    FUNCTIONAL DISSECTION OF ONCOGENIC ENHANCERS IN T-CELL LEUKEMIA (Private)

    Jul 1 2014 - Jun 30 2017

    NEW SYNERGISTIC DRUG COMBINATIONS FOR THE TREATMENT OF T-ALL (Private)

    Jul 1 2016 - Jun 30 2017

    PROGNOSTIC BIOMARKERS AND DISEASE DRIVERS IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (Federal Gov)

    Mar 1 2016 - Feb 28 2017

    THE ROLE OF FBXL4 IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (Federal Gov)

    Jan 15 2013 - Jan 14 2017

    THE ROLE OF FBXL4 IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (Federal Gov)

    Jan 15 2013 - Jan 14 2017

    SOHN COLLABORATIVE FOR PEDIATRIC CANCER RESEARCH (Private)

    Apr 22 2014 - Dec 31 2016

    MECHANISMS AND TARGETED INHIBITION OF NT5C2 MUTATIONS IN RELAPSED ALL (Private)

    Jul 1 2014 - Jun 30 2016

    TARGETING EPIGENETIC PLASTICITY AND DRUG RESISTANCE IN PEDIATRIC CANCER (Private)

    Jul 1 2015 - Jun 30 2016

    OVERCOMING RESISTANCE IN RELAPSED ALL (Private)

    Jul 1 2015 - Jun 30 2016

    NEW SYNERGISTIC DRUG COMBINATIONS FOR THE TREATMENT OF T-ALL (Private)

    Apr 1 2015 - Mar 31 2016

    THE ROLE OF PHF6 IN LEUKEMIA STEM CELL SELF-RENEWAL (Private)

    Apr 1 2015 - Mar 31 2016

    THE ROLE OF NOTCH1 IN CHRONIC LYMPHOCYTIC LEUKEMIA (Private)

    Mar 1 2014 - Feb 29 2016

    MECHANISMS OF CHEMOTHERAPY RESISTANCE IN ACUTE LYMPHOBLASTIC LEUKEMIA (Private)

    Jan 1 2014 - Dec 31 2015

    CLONAL EVOLUTION AND CHEMOTHERAPY RESISTANCE IN ALL (Private)

    Jan 1 2014 - Dec 31 2015

    DEVELOPING NEW COMBINATION THERAPIES IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (Private)

    Jan 1 2015 - Dec 31 2015

    PERSHING SQUARE SOHN CELL SORTER EQUIPMENT GRANT (Private)

    Oct 1 2015 - Dec 31 2015

    THE ROLE OF PHF6 IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (Federal Gov)

    Dec 3 2010 - Nov 30 2015

    THE ROLE OF PHF6 IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (Federal Gov)

    Dec 3 2010 - Nov 30 2015

    THE EPIGENETIC ROLE OF PHF6 IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (Private)

    Oct 1 2014 - Sep 30 2015

    FUNCTIONAL DISSECTION OF ONCOGENIC ENHANCERS IN T-ALL (Private)

    Jul 1 2015 - Jul 1 2015

    LONG RANGE ENHANCER REGULATION OF MYC IN T-CELL TRANSFORMATION (Private)

    Jul 1 2012 - Jun 30 2015

    THE ROLE OF RUNX1 MUTATIONS IN THE PATHOGENESIS OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (Private)

    Jul 1 2013 - Jun 30 2015

    NEW SYNERGISTIC DRUG COMBINATIONS FOR THE TREATMENT OF T-ALL (Private)

    Apr 1 2013 - Mar 31 2015

    THE GENETICS OF PERIPHERAL T-CELL LYMPHOMAS (Private)

    Oct 1 2011 - Sep 30 2014

    THE ROLE OF NT5C2 IN DRUG RESISTANCE AND RELAPSE OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (Private)

    Sep 1 2013 - Aug 31 2014

    THE ROLE OF NT5C2 IN RELAPSED AND REFRACTORY T-ALL (Private)

    Jul 1 2013 - Jun 30 2014

    TARGETING GLUCOCORTICOID RESISTANCE IN T-ALL (Private)

    Jul 1 2011 - Jun 30 2014

    TARGETING GENETIC AND METABOLIC NETWORKS IN T-ALL (Private)

    Jun 1 2011 - May 31 2014

    THEROLE OF AKT SIGNALING IN NOTCH1 INDUCED LEUKEMIAS (Federal Gov)

    Apr 1 2008 - Jan 31 2014

    THEROLE OF AKT SIGNALING IN NOTCH1 INDUCED LEUKEMIAS (Federal Gov)

    Apr 1 2008 - Jan 31 2014

    TARGETING CHEMOTHERAPY RESISTANCE IN T-ALL (Private)

    Jan 1 2012 - Dec 31 2013

    MECHANISMS OF T-CELL LEUKEMOGENESIS INDUCED BY NOTCH1 (Federal Gov)

    Dec 1 2006 - Nov 30 2013

    TRAINING ON TRANSLATIONAL RESEARCH IN CANCER (Private)

    Nov 1 2012 - Oct 31 2013

    ANALYSIS OF PF-03084014 AND GLUCOCORTICO IN (Private)

    Jul 1 2011 - Sep 13 2013

    TARGETING CLASS I PI3KS IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (Federal Gov)

    Aug 1 2010 - Aug 31 2013

    THE ROLE OF RUNX1 IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (Private)

    Jul 1 2012 - Jun 30 2013

    THE ROLE OF PHF6 IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (Federal Gov)

    Jul 1 2011 - Jun 30 2013

    MECHANISMS OF T-CELL LEUKEMOGENESIS INDUCED BY NOTCH1 (Federal Gov)

    Feb 15 2012 - Feb 14 2013

    PRECLINICAL STUDIES WITH GAMMA SECRETASE INHIBITORS (GSIS) A ND GLUCOCORTICOIDS IN T-ALL (Private)

    Nov 2 2011 - Nov 1 2012

    CLASS I P13KS AS A THERAPEUTIC TARGET IN ACUTE LYMPHOBLASTIC LEUKEMIA (Private)

    Oct 1 2009 - Sep 30 2012

    NOVEL NOTCH INHIBITORS AND ENHANCERS (Private)

    Oct 1 2007 - Sep 30 2012

    SYSTEMS BIOLOGY OF TUMOR PROGRESSION AND DRUG-RESISTANCE (Federal Gov)

    Sep 30 2009 - Aug 31 2012

    MECHANISMS IF T-CELL LEUKEMOGENESIS INDUCED BY NOTCH1 (Private)

    Jul 1 2007 - Jun 30 2012

    THE GENETICS OF RELAPSED AND REFRACTORY T-ALL (Private)

    Jul 1 2011 - Jun 30 2012

    THE ROLE OF RUNX1 IN T-ALL (Private)

    Apr 1 2011 - Mar 31 2012

    TARGETING GLUCOCORTICOID RESISTANCE IN T-ALL: A SYSTEMS BIOL OGY APPROACH (Private)

    Jan 1 2010 - Dec 31 2011

    COMBINATION THERAPY WITH NOTCH INHIBITORS AND GLUCOCORTICOID S IN T-ALL (Private)

    Oct 1 2007 - Sep 30 2011

    PRECLINICAL STUDIES WITH GSI PF-03084014 AND GLUCOCORTICOIDS IN TALL (Private)

    Aug 3 2009 - Jun 30 2011

    THE ROLE OF HES1 IN T CELL DEVELOPMENT (Private)

    Jul 1 2007 - Jun 30 2011

    THE ROLE OF PHF6 IN THE PATHOGENESIS OF T-ALL (Private)

    May 1 2010 - Apr 30 2011

Publications

  1. GATA3-Controlled Nucleosome Eviction Drives MYC Enhancer Activity in T-cell Development and Leukemia
    Belver L, Yang AY, Albero R, Herranz D, Brundu FG, Quinn SA, Pérez-Durán P, Álvarez S, Gianni F, Rashkovan M, Gurung D, Rocha PP, Raviram R, Reglero C, Cortés JR, Cooke AJ, Wendorff AA, Cordó V, Meijerink JP, Rabadan R, Ferrando AA
    Cancer Discov. 2019.
    PMID: 31519704, DOI: 10.1158/2159-8290.CD-19-0471
  2. Phf6 Loss Enhances HSC Self-Renewal Driving Tumor Initiation and Leukemia Stem Cell Activity in T-ALL
    Wendorff AA, Quinn SA, Rashkovan M, Madubata CJ, Ambesi-Impiombato A, Litzow MR, Tallman MS, Paietta E, Paganin M, Basso G, Gastier-Foster JM, Loh ML, Rabadan R, Van Vlierberghe P, Ferrando AA
    Cancer Discov. 2019.
    PMID: 30567843, DOI: 10.1158/2159-8290.CD-18-1005
  3. Oncogenic hijacking of the stress response machinery in T cell acute lymphoblastic leukemia
    Kourtis N, Lazaris C, Hockemeyer K, Balandrán JC, Jimenez AR, Mullenders J, Gong Y, Trimarchi T, Bhatt K, Hu H, Shrestha L, Ambesi-Impiombato A, Kelliher M, Paietta E, Chiosis G, Guzman ML, Ferrando AA, Tsirigos A, Aifantis I
    Nat Med. 2018.
    PMID: 30038221, DOI: 10.1038/s41591-018-0105-8
  4. Structure and Mechanisms of NT5C2 Mutations Driving Thiopurine Resistance in Relapsed Lymphoblastic Leukemia
    Dieck CL, Tzoneva G, Forouhar F, Carpenter Z, Ambesi-Impiombato A, Sánchez-Martín M, Kirschner-Schwabe R, Lew S, Seetharaman J, Tong L, Ferrando AA
    Cancer Cell. 2018.
    PMID: 29990496, DOI: 10.1016/j.ccell.2018.06.003
  5. Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia
    Tzoneva G, Dieck CL, Oshima K, Ambesi-Impiombato A, Sánchez-Martín M, Madubata CJ, Khiabanian H, Yu J, Waanders E, Iacobucci I, Sulis ML, Kato M, Koh K, Paganin M, Basso G, Gastier-Foster JM, Loh ML, Kirschner-Schwabe R, Mullighan CG, Rabadan R, Ferrando AA
    Nature. 2018.
    PMID: 29342136, DOI: 10.1038/nature25186
  6. Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia
    Herranz D, Ambesi-Impiombato A, Sudderth J, Sánchez-Martín M, Belver L, Tosello V, Xu L, Wendorff AA, Castillo M, Haydu JE, Márquez J, Matés JM, Kung AL, Rayport S, Cordon-Cardo C, DeBerardinis RJ, Ferrando AA
    Nat Med. 2015.
    PMID: 26390244, DOI: 10.1038/nm.3955
  7. A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia
    Herranz D, Ambesi-Impiombato A, Palomero T, Schnell SA, Belver L, Wendorff AA, Xu L, Castillo-Martin M, Llobet-Navás D, Cordon-Cardo C, Clappier E, Soulier J, Ferrando AA
    Nat Med. 2014.
    PMID: 25194570, DOI: 10.1038/nm.3665
  8. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas
    Palomero T, Couronné L, Khiabanian H, Kim MY, Ambesi-Impiombato A, Perez-Garcia A, Carpenter Z, Abate F, Allegretta M, Haydu JE, Jiang X, Lossos IS, Nicolas C, Balbin M, Bastard C, Bhagat G, Piris MA, Campo E, Bernard OA, Rabadan R, Ferrando AA
    Nat Genet. 2014.
    PMID: 24413734, DOI: 10.1038/ng.2873
  9. Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia
    Piovan E, Yu J, Tosello V, Herranz D, Ambesi-Impiombato A, Da Silva AC, Sanchez-Martin M, Perez-Garcia A, Rigo I, Castillo M, Indraccolo S, Cross JR, de Stanchina E, Paietta E, Racevskis J, Rowe JM, Tallman MS, Basso G, Meijerink JP, Cordon-Cardo C, Califano A, Ferrando AA
    Cancer Cell. 2013.
    PMID: 24291004, DOI: 10.1016/j.ccr.2013.10.022
  10. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL
    Tzoneva G, Perez-Garcia A, Carpenter Z, Khiabanian H, Tosello V, Allegretta M, Paietta E, Racevskis J, Rowe JM, Tallman MS, Paganin M, Basso G, Hof J, Kirschner-Schwabe R, Palomero T, Rabadan R, Ferrando A
    Nat Med. 2013.
    PMID: 23377281, DOI: 10.1038/nm.3078
  11. Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALL
    Della Gatta G, Palomero T, Perez-Garcia A, Ambesi-Impiombato A, Bansal M, Carpenter ZW, De Keersmaecker K, Sole X, Xu L, Paietta E, Racevskis J, Wiernik PH, Rowe JM, Meijerink JP, Califano A, Ferrando AA
    Nat Med. 2012.
    PMID: 22366949, DOI: 10.1038/nm.2610
  12. The TLX1 oncogene drives aneuploidy in T cell transformation
    De Keersmaecker K, Real PJ, Gatta GD, Palomero T, Sulis ML, Tosello V, Van Vlierberghe P, Barnes K, Castillo M, Sole X, Hadler M, Lenz J, Aplan PD, Kelliher M, Kee BL, Pandolfi PP, Kappes D, Gounari F, Petrie H, Van der Meulen J, Speleman F, Paietta E, Racevskis J, Wiernik PH, Rowe JM, Soulier J, Avran D, Cavé H, Dastugue N, Raimondi S, Meijerink JP, Cordon-Cardo C, Califano A, Ferrando AA
    Nat Med. 2010.
    PMID: 20972433, DOI: 10.1038/nm.2246
  13. PHF6 mutations in T-cell acute lymphoblastic leukemia
    Van Vlierberghe P, Palomero T, Khiabanian H, Van der Meulen J, Castillo M, Van Roy N, De Moerloose B, Philippé J, González-García S, Toribio ML, Taghon T, Zuurbier L, Cauwelier B, Harrison CJ, Schwab C, Pisecker M, Strehl S, Langerak AW, Gecz J, Sonneveld E, Pieters R, Paietta E, Rowe JM, Wiernik PH, Benoit Y, Soulier J, Poppe B, Yao X, Cordon-Cardo C, Meijerink J, Rabadan R, Speleman F, Ferrando A
    Nat Genet. 2010.
    PMID: 20228800, DOI: 10.1038/ng.542
  14. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia
    Real PJ, Tosello V, Palomero T, Castillo M, Hernando E, de Stanchina E, Sulis ML, Barnes K, Sawai C, Homminga I, Meijerink J, Aifantis I, Basso G, Cordon-Cardo C, Ai W, Ferrando A
    Nat Med. 2009.
    PMID: 19098907, DOI: 10.1038/nm.1900
  15. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia
    Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, Ciofani M, Caparros E, Buteau J, Brown K, Perkins SL, Bhagat G, Agarwal AM, Basso G, Castillo M, Nagase S, Cordon-Cardo C, Parsons R, Zúñiga-Pflücker JC, Dominguez M, Ferrando AA
    Nat Med. 2007.
    PMID: 17873882, DOI: 10.1038/nm1636

For a complete list of publications, please visit PubMed.gov